Prestige Biologics Co., Ltd. (KOSDAQ:334970)

South Korea · Delayed Price · Currency is KRW

1,798.00

-6.00 (-0.33%)

At close: Jul 28, 2026

Prestige Biologics Financials Overview

Financials in millions KRW. Fiscal year is July - June.

Millions KRW. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	18,029	12,533	2,169	1,746	15.57	3,227
Revenue Growth	168.64%	477.82%	24.24%	11115.88%	-99.52%	-
Gross Profit	-18,878	-15,984	-8,844	493.75	-8.71	2,347
Operating Income	-43,854	-33,682	-33,430	-40,043	-36,631	-26,837
Net Income	-35,425	-27,469	-29,374	-39,442	-49,718	-39,378
Earnings Per Share	-410.69	-372.51	-480.00	-672.37	-960.73	-885.98
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2024	FY 2023
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023
Antibody Drugs	1,479	3,164
Other than Service	689.62	296.77

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	664.67	1,582	29,507	45,435	15,383	36,775
Total Debt	85,093	91,461	173,043	160,016	118,619	78,112
Net Cash (Debt)	-84,428	-89,879	-143,536	-114,581	-103,236	-41,337
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-978.82	-1218.84	-2345.53	-1953.28	-1994.89	-930.05

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	8,142	-18,308	-8,345	-24,830	-34,124	-25,750
Capital Expenditures	-7,215	-5,226	-8,522	-35,435	-84,642	-97,392
Free Cash Flow	926.76	-23,534	-16,867	-60,265	-118,767	-123,142
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-104.71%	-127.53%	-	28.28%	-55.97%	72.73%
Operating Margin	-243.25%	-268.74%	-1541.23%	-2293.61%	-235333.31%	-831.68%
Pretax Margin	-196.49%	-219.17%	-1354.23%	-2259.19%	-319407.01%	-1220.33%
Profit Margin	-196.49%	-219.17%	-1354.23%	-2259.19%	-319407.01%	-1220.33%
FCF Margin	5.14%	-187.77%	-777.63%	-3451.94%	-763002.69%	-3816.18%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 28, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	7.75	22.64	113.13	156.11	11855.95	140.44